Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

opportunities. In addition, by selectively reducing cash pay debt,

Angiotech expects the remaining royalty revenue derived from its

partners BSC and Cook Group Incorporated ("Cook") will be adequate to

service any remaining debt. The various assets, including the royalty

business and API equity stake, owned by Angiotech will also allow

continued exploration of additional financing and strategic

alternatives to potentially further reduce or eliminate remaining

Angiotech debt.

Transaction Description and Plan

- Transaction Process. In late 2007 and early 2008, Angiotech

management and its Board of Directors discussed and reviewed various

financial and strategic alternatives, with the goal of evaluating and

pursuing selected opportunities to reduce debt, mitigate certain

risks and improve shareholder value. As a result of this review,

Angiotech conducted a process, together with its financial and legal

advisors, in which multiple potential investors were contacted to

evaluate an investment in API. Angiotech received and evaluated

multiple proposals over the past several months, and ultimately

concluded negotiations with Ares and New Leaf.

- Formation of API. API has been established as a Delaware corporation,

with principal executive offices in Vancouver, British Columbia.

Immediately prior to the close of the transaction, Angiotech and API

will enter into agreements to transfer to API certain assets and

liabilities of Angiotech, which primarily include the various

operating business assets and product development programs of

Angiotech, and exclude (i) intellectual property and royalty revenue

related to BSC's TAXUS paclitaxel-eluting coronary stent system; (ii)

potential royalty and other income from certain
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Fast, semi-automatic ... chemistry in documents ChemAxon , ... consulting services for life science research, launches ChemCurator, ... Markush structures from documents. Markush structures ... however generating and understanding Markush structures is a ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
(Date:9/30/2014)... The custom stainless steel fabrication company HOLLOWAY AMERICA ... Boston Area Chapter of ISPE (International Society for Pharmaceutical ... Wed., Oct. 1 at Gillette Stadium Clubhouse in Foxborough, ... ISPE Boston’s long history, with more than 375 exhibitors ... , HOLLOWAY AMERICA President David Simpson is looking forward ...
(Date:9/30/2014)... September 30, 2014 On September 11, Pharma ... Sherley in anticipation of a session that he will lead ... Summit,” scheduled for February 17-18, 2015 in London. In ... IQ asked Dr. Sherley to respond to several questions on ... challenges to evaluating stem cell toxicity, and future trends in ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4
... Arginine vasopressin (AVP) receptor antagonist now approved in single-use ... ... 22 Astellas Pharma US, Inc. today,announced that the U.S. ... of Vaprisol: Vaprisol(R) (conivaptan hydrochloride,injection) Premixed in 5% Dextrose. Discovered ...
... November 18, 2008, WITTEN, Germany, October 22 ... fiscal year,ended June 30, 2008, on October 21. According ... SEC the company yielded sales of its cosmetics and ... a decrease,of 44% as compared with sales revenues of ...
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical ... that it will present at three upcoming investor conferences:, ... the Hyatt Regency in La,Jolla, Calif. on Monday, October ... -- Oppenheimer,s 19th Annual Healthcare Conference to be ...
Cached Biology Technology:FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses 2Halozyme Therapeutics to Present at Upcoming Investor Conferences 2
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/30/2014)... ARLINGTON HEIGHTS, Ill. (September 30, 2014) People who ... they can do to control their asthma besides properly ... to a new article in the Annals of ... the American College of Allergy, Asthma and Immunology (ACAAI), ... by examining their lifestyle. The woman described in the ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2
... The U.S. Food and Drug Administration (FDA) granted market ... bionic eye to be approved for patients in the ... with support from the National Science Foundation (NSF). ... transmits images from a small, eye-glass-mounted camera wirelessly to ...
... be an early step toward new treatments for people with ... probiotic supplement can help male mice produce healthier bones. ... researchers report in the Journal of Cellular Physiology . ... bone loss, though it,s unclear exactly why," said lead author ...
... that cold-blooded animals, such as worms, flies and fish ... known exactly why. , Researchers at the University of ... that promotes longevity of roundworms in cold environmentsand this ... , "This raises the intriguing possibility that exposure to ...
Cached Biology News:Artificial retina receives FDA approval 2Artificial retina receives FDA approval 3Artificial retina receives FDA approval 4Artificial retina receives FDA approval 5Building healthy bones takes guts 2Stay cool and live longer? 2
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids 926-941 ... immunoaffinity purified Quality Assurance ... lysates from HeLa cells. Stability ...
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
MarrowMAX Bone Marrow Medium...
Replacement Parts for Electrophoresis Apparatus...
Biology Products: